Ophthopedia reviews multi-omics in glaucoma

Glaucoma is an optic-nerve disease that steals vision slowly and usually permanently. The frustrating part is that doctors can lower eye pressure and still watch some patients keep getting worse. That gap is why this new review matters. It argues that glaucoma is bigger than pressure alone, and that the best way to see the full disease is to stack multiple “omes” — genes, RNA, proteins, and metabolites — on top of each other. ### What does “multi-omics” actually mean? Basically, it means looking at several biological layers at once. Genomics asks which DNA variants raise risk. Transcriptomics asks which genes are switched on or off. Proteomics tracks the proteins cells are actually using. Metabolomics looks at the small molecules left behind by energy use, stress, and cell damage. On their own, each layer is partial. Together, they can show a chain from inherited risk to cell behavior to tissue injury. ### Why is glaucoma a good fit for this? Because glaucoma is messy. Elevated intraocular pressure matters, but it is not the whole story. Retinal ganglion cell death also seems tied to neuroinflammation, mitochondrial stress, vascular dysfunction, extracellular-matrix remodeling, and subtype-specific biology across primary open-angle glaucoma, angle-closure glaucoma, and normal-tension glaucoma. A single biomarker has a hard time capturing all that. A multi-omics map has a better shot. ### What is the review saying changed? The review’s main claim is that the field has moved past isolated omics snapshots. Over the past decade, glaucoma studies have started connecting risk genes to downstream proteins, metabolic pathways, and candidate interventions. That is the real shift — from “here is a suspicious molecule” to “here is a plausible pathway that keeps showing up across datasets.” A few themes recur. Inflammation and immune signaling show up repeatedly. So do mitochondrial and broader metabolic problems — especially pathways linked to oxidative stress and neurodegeneration. Structural remodeling matters too, including extracellular-matrix pathways that may shape optic-nerve vulnerability and aqueous outflow. In plain English, glaucoma looks less like one broken dial and more like a stressed system failing in several connected places. ### Are there actual biomarker candidates yet? Yes — and that is where the story gets more concrete. A February 2026 IOVS proteomics study identified 26 plasma proteins with putative causal links to glaucoma, with EFEMP1 standing out in a prospective UK Biobank analysis. Another 2026 integrative study highlighted NRP2 and SMAD1, plus subtype-linked signals like LTBP2 and MANSC4, and tied some of those effects to sphingolipids, acylcarnitines, and bile-acid-related metabolites. ### Does that mean new treatments are close? Not exactly. The catch is that biomarker discovery is easier than clinical translation. A protein can look statistically convincing and still fail as a screening test or drug target. Eye disease adds extra hurdles — tissue access is hard, blood markers may not cleanly reflect what is happening in the optic nerve, and glaucoma subtypes do not behave the same way. ### What matters now? Because it helps frame glaucoma as a precision-medicine problem. If different patients are being pushed toward damage by different mixes of pressure stress, inflammation, metabolism, and connective-tissue biology, then future care may need matched diagnostics and matched therapies rather than one broad treatment logic for everyone. That idea has been floating around for years. Multi-omics is what might finally make it testable. ### Bottom line? The review is not announcing a cure. But it does mark a real change in how glaucoma is being studied — from a mostly pressure-centered disease to a network disease with measurable molecular signatures. If those signatures hold up in larger and more diverse cohorts, they could reshape how glaucoma gets detected, classified, and treated.